Thalidomide inhibited the synthesis of IgM and IgG whereas Thalidomide + Dexamethasone and Dexamethasone alone acted as co-stimulants with pokeweed and enhanced their synthesis

International Immunopharmacology

Volumn 10, Issue 4, 2010, Pages 487-492

  Shannon, E J ^a   Sandoval, F ^a  

^a U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

Author keywords

Dexamethasone; Immunoglobulin; Thalidomide

Indexed keywords

DEXAMETHASONE; DNA; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 2; INTERLEUKIN 6; POKEWEED MITOGEN; THALIDOMIDE;

ARTICLE; CELL PROLIFERATION; CELL STIMULATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; ERYTHEMA NODOSUM LEPROSUM; HUMAN; HUMAN CELL; IMMUNOGLOBULIN PRODUCTION; MONONUCLEAR CELL; MULTIPLE MYELOMA; POKEWEED; PRIORITY JOURNAL; WALDENSTROEM MACROGLOBULINEMIA;

ADJUVANTS, IMMUNOLOGIC; ANTI-INFLAMMATORY AGENTS; B-LYMPHOCYTES; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; DEXAMETHASONE; DRUG INTERACTIONS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; INTERLEUKIN-6; MONOCYTES; POKEWEED MITOGENS; THALIDOMIDE;

EID: 77949655465     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2010.01.010     Document Type: Article

References (37)

1. Roccaro A.M., Ghobrial I.M., Blotta S., Treon S.P., Malagola M., Anderson K.C., et al. Advances in the treatment of monoclonal gammopathies: the emerging role of targeted therapy in plasma cell dyscrasias. Biologics 2 3 (2008) 419-431
2. Treon S.P., Soumerai J.D., Branagan A.R., Hunter Z.R., Patterson C.J., and Ioakimidis L. Thalidomide and rituximab in Waldenström macroglobulinemia. Blood 112 12 (2008) 4452-4457
3. Ridley D.S. A bacterologic study of erythemal nodosum leprosum. Int. J. Lepr. Other Mycobacterial Dis. 28 (1960) 254-266
4. Ridley M.J., and Ridley D.S. The immunopathology of erythema nodosum leprosum: the role of extra-vascular complexes. Lepr. Rev. 54 (1983) 95-107
5. Wemambu S.N., Turk J.L., Waters M.F., and Reese R.J. Erythema nodosum leprosum: a clinical manifestation of the Arthus phenomenon. Lancet 2 (1969) 933-935
6. Scollard D.M., Bhoopat L., Kestens L., Vanham G., Douglas J.T., and Moad J. Immune complexes and antibody levels in blisters over human leprosy skin lesions with or without erythema nodosum leprosum. Clin. Immunol. Immunopathol. 63 3 (1992) 230-236
7. Ridley D.S. Skin biopsy of leprosy. Histological interpretation and clinical application. Documenta Geigy (1977), Ciba-Geigy Ltd.,, Basel, Switzerland
8. Lai-A-Fat R., Jin J., and van Furth R. In vitro synthesis of anti-mycobacterial antibodies in biopsies from skin lesions of leprosy patients. Infect. Immun. 27 (1980) 297-301
9. International Meloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders. Br. J. Haematol. 121 (2003) 749-1757
10. Waldmann T.A., and Broder S. Polyclonal B-cell activators in the study of the regulation of immunoglobulin synthesis in the human system. Adv. Immunol. 32 (1982) 1
11. Cooper D.A., Duckett M., Hansen P., Petts V., and Penny R. Glucocorticosteroid enhancement of immunoglobulin synthesis by pokeweed mitogen-stimulated human lymphocytes. III. Common variable immunodeficiency. Clin. Exp. Immunol. 45 2 (1981) 399-408
12. Fauci A.S., Pratt K.R., and Whalen G. Activation of human B lymphocytes. IV. Regulatory effects of corticosteroids on the triggering signal in the plaque-forming cell response of human peripheral blood B lymphocytes to polyclonal activation. J. Immunol. 119 2 (1977) 598-603
13. Shannon E.J., Sandoval F., and Krahenbuhl J.L. Hydrolysis of thalidomide abrogates its ability to enhance mononuclear cell synthesis of IL-2 as well as its ability to suppress the synthesis of TNF-α. Immunopharmacology 36 1 (1997) 9-15
14. Zwingenberger K., and Wnendt S. Immunomodulation by thalidomide: systematic review of the literature and of unpublished observations. J. Inflamm. 46 4 (1996) 177-211
15. Weber D., Rankin K., Gavino M., et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J. of Clin. Oncol. 21 (2003) 16-19
16. Lauta V.M. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer 97 10 (2003) 2440-2452
17. Shannon E.J., and Sandoval F. Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with Concanavalin-A, Staphylococcal enterotoxin A, and purified protein derivative. Immunopharmacology 31 1 (1995) 109-116
18. Haslett P.A., Corral L.G., Albert M., and Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J. Exp. Med. 187 11 (1998) 1885-1892
19. Shannon E., Noveck R., Sandoval F., and Kamath B. Thalidomide suppressed IL-1beta while enhancing TNF-alpha and IL-10, when cells in whole blood were stimulated with lipopolysaccharide. Immunopharmacol Immunotoxicol 30 3 (2008) 447-457
20. Nakagawa N., Nakagawa T., Volkman D.J., Ambrus Jr. J.L., and Fauci. The role of interleukin 2 in inducing Ig production in a pokeweed mitogen-stimulated mononuclear cell system. J. Immunol. 138 3 (1987) 795-801
21. Ralph P., Jeong G., Welte K., Mertelsmann R., Rabin H., and Henderson L.E. Stimulation of immunoglobulin secretion in human B lymphocytes as a direct effect of high concentrations of IL 2. J. Immunol. 133 5 (1984) 2442-2445
22. Akira S., Taga T., and Kishimoto T. Interleuckin-6 in biology and medicine. Adv. Immunol. 54 (1993) 178 Academic Press
23. Shannon E.J., Miranda R.O., Morales M.J., and Hastings R.C. Inhibition of de novo IgM antibody synthesis by thalidomide as a relevant mechanism of action in leprosy. Scand. J. Immunol. 13 6 (1981) 553-562
24. Gusdon J.P., and Cohen C. Effect of thalidomide on the antibody response. A. J. Obstet. Gynaecol. 100 (1964) 952-956
25. Arala-Chaves M., Vilanova M., Ribeiro A., and Pinto J. Immunostimulatory effect of thalidomide in normal C57BL/6 mice is compatible with stimulation of a highly connected central immune system. Scand. J. Immunol. 40 5 (1994) 535-542
26. Descotes J., Tedone R., and Evreux J. Enhancement of antibody response and delayed-type hypersensitivity by thalidomide in mice. Fundam. Clin. Pharmacol. 2 6 (1988) 493-497
27. Teraoka H., Mikoshiba M., Takase K., Yamamoto K., and Tsukada K. Reversible G1 arrest induced by dimethyl sulfoxide in human lymphoid cell lines: dimethyl sulfoxide inhibits IL-6-induced differentiation of SKW6-CL4 into IgM-secreting plasma cells. Exp. Cell Res. 222 1 (1996) 218-224
28. Ponzio G., Loubat A., Rochet N., Turchi L., Rezzonico R., Farahi Far D., et al. Early G1 growth arrest of hybridoma B cells by DMSO involves cyclin D2 inhibition and p21[CIP1] induction. Oncogenes 17 9 (1998) 1159-1166
29. Eriksson T, Pharmacokinetics of the enantiomers of thalidomide PhD Thesis. Department of Clinical Pharmacology, Lund University, Lund and Hospital Pharmacy, Malmö University Hospital, Sweden, 1997;287:388-97.
30. Claman H.N. Corticosteroids and lymphoid cells. New Eng. J. Med. (1972) 287-388
31. Naafs B. Current views on reactions in leprosy. Indian J. Lepr. 72 1 (2000) 97-122
32. Lahiri R., Sandoval F., Krahenbuhl J., and Shannnon E. Activation of complement by Mycobacterium leprae requires disruption of the bacilli. Lepr. Rev. 79 3 (2008) 311-314
33. Tadesse A., and Shannon E.J. Effects of thalidomide on intracellular Mycobacterium leprae in normal and activated macrophages. Clin. and Diag. Lab. Immunol 12 1 (2005) 130-133
34. Levis W.R., Meeker H.C., Schuller-Levis G., Sersen E., and Schwerer B. IgM and IgG antibodies to phenolic glycolipid I from Mycobacterium leprae in leprosy: insight into patient monitoring, erythema nodosum leprosum, and bacillary persistence. J. Invest. Dermatol 86 5 (1986) 529-534
35. Singhal S., Mehta J., Desikan R., Ayers D., Roberson P., and Eddlemon P. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341 21 (1999) 1565-1571
36. Israyelyan A., Shannon E.J., Baghian A., Kearney M.T., and Kousoulas K.G. Thalidomide suppressed the growth of 4T1 cells into solid tumors in Balb/c mice in a combination therapy with the oncolytic fusogenic HSV-1 OncdSyn. Cancer Chemother. Pharmacol. 64 6 (2009) 1201-1210
37. Lu J., Brain D., Palmer B., Kestell P., Browett P., Baguley G.M., et al. Thalidomide metabolites in mice and patients with multiple myeloma. Clin. Cancer Res. 9 (2003) 1680-1688